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enomic research has the 
potential to improve global 
health by elucidating basic 
mechanisms of disease, susceptibility, 
and resistance, thereby guiding 
the development of preventive 
interventions [1].  Recently developed 
methods for exploring how human 
genetic variation affects resistance are 
likely to provide strategic clues about 
vaccine development for researchers 
working on malaria, HIV, tuberculosis, 
and other diseases of the developing 
world [2]. 
A key scientiﬁ  c challenge facing the 
genomic epidemiology of common 
diseases is the vast number of genetic 
and environmental factors potentially 
involved. Taken together with the fact 
that certain genetic effects may be 
more apparent in some populations 
than others, this means that genomic 
epidemiology studies must often 
include large numbers of participants 
across multiple populations. Such 
studies pose not only scientiﬁ  c but also 
ethical challenges, including how to 
achieve valid consent for the collection 
of large numbers of samples and 
phenotypic information across a variety 
of diverse, often resource-poor settings.
While there are many statements 
setting out ethical principles for 
biomedical research in developing 
countries [3–5], there are few validated 
methods by which to apply those 
principles to large-scale genomic 
studies. While the concept of “valid 
consent” as codiﬁ  ed in the Declaration 
of Helsinki has long been established 
as a cornerstone of ethical research, 
the interpretation of this concept in 
practice is not straightforward [6–8] 
and is further complicated by the fact 
that what guidance there is on consent 
tends to be biased towards clinical 
trials and does not address novel issues 
raised in genomic studies [8].
Drawing on experience gained 
from a long-term programme of basic 
and applied research on malaria in 
Mali, including smaller-scale genetic 
studies [9,10], and from current 
efforts to bring together malaria 
research groups across multiple centres 
on four continents, we discuss the 
practical challenges of deﬁ  ning and 
obtaining valid consent for genomic 
epidemiological research in developing 
countries. 
Ethical Issues Related to Consent
A number of guiding principles for 
participation in research in developing 
countries have been established 
in guidelines, reports, and notes 
from the ﬁ  eld [3,4,11–14]. While 
these principles provide a helpful 
framework, they leave unanswered a 
number of important questions. For 
example, several guidelines suggest 
that unfamiliar concepts should be 
explained using analogies—but provide 
no guidance for how in practice one 
might create useful analogies for, for 
example, concepts such as “gene”, 
“DNA”, or “genetic database”.
In what follows, and bearing in 
mind that valid consent is a process 
rather than a simple one-off matter 
of signing a form, we consider a 
number of challenges in relation 
to the achievement of consent in 
genomic epidemiology. We do so 
under ﬁ  ve headings: (1) disclosure 
and comprehension of information, 
(2) voluntariness, (3) competence, 
(4) “broad” or “open-ended” consent 
for future use of samples, and (5) 
community dimensions of consent 
[15].
The discussion of these challenges 
is made more concrete by the 
accompanying Boxes 1–4, which 
set out important principles that 
could be included in an informed 
consent form. Each principle includes 
examples of the actual language 
currently used in such consent forms. 
In selecting these examples, we drew 
on existing consent forms used for 
genetic studies of malaria in Blantyre, 
Malawi (a collaboration of Malawi 
College of Medicine, Wellcome Trust 
Research Laboratories, and Blantyre 
Malaria Project), at Kiliﬁ  , Kenya 
(a collaboration of Kenya Medical 
Research Institute and Wellcome 
Trust Research Unit), Banjul, The 
Gambia (Medical Research Council 
Laboratories), Navrongo, Ghana (a 
collaboration of Navrongo Health 
Research Centre and Noguchi 
Memorial Research Institute), and in 
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Bandiagara, Mali (Malaria Research 
and Training Centre, University of 
Bamako). These examples show how 
key elements of the consent form 
have been addressed in practice. A 
more detailed exposition of the role 
of informed consent forms is also 
included below.
1. Disclosure and Comprehension 
of Information
To be valid, consent to participate in 
research must be based on adequate 
information and understanding. 
Participants must have sufﬁ  cient 
understanding of the purpose of the 
research, of what participation in the 
research means for them (and/or 
their child), of what will happen 
to samples and records during and 
after the study, and of what steps are 
being taken to ensure conﬁ  dentiality, 
security, and privacy. In addition, 
research participants must be aware 
of the fact that they can withdraw 
from the research at any time and 
should know how to go about this. 
Participants should, in our view, also 
be informed about the beneﬁ  ts (if any) 
that are likely to accrue to researchers, 
individuals, and communities as 
a result of the research. Each of 
these elements presents signiﬁ  cant 
difﬁ  culty in research settings where 
linguistic and cultural practices vary 
considerably. In our experience, three 
key challenges in this respect are: 
linguistic and conceptual barriers to 
conveying key concepts; the design and 
provision of appropriate education 
to help participants understand the 
implications of involvement; and the 
question of how best to convey the 
purpose of the research and the value 
of participation in it.
Linguistic and conceptual barriers. 
Linguistic and conceptual barriers are 
widely discussed in the literature [16]. 
In genomic research, one of the most 
intractable challenges is how to convey 
key genetic concepts in a clear and 
understandable manner. Experiences 
from the ﬁ  eld show that the process 
of working out comprehensible 
language is of crucial importance 
in conveying such information, 
whether in writing or verbally [17]. 
This process will involve researchers, 
institutional review bodies, funders, 
and communities jointly working out 
commonly accepted language, oral 
and/or written, for particular concepts. 
It also means translating consent forms 
and any accompanying information 
and scripts for oral explanation into 
local languages and ensuring that they 
are independently back-translated for 
validation. If discrepancies in back-
translations are found, researchers will 
need to search for different channels of 
communication within the community 
to deal with them. For instance, in 
genetic studies of malaria in Mali, 
scientists work with school teachers in 
the village. If teachers are involved in 
the building of consent processes, they 
can continue teaching and responding 
to questions about the project when the 
investigators are not present.
Educational activities. The 
requirement for comprehensible 
transmission of information to and 
discussions about good practice with 
participants must be tailored to the 
local setting. In Mali, for instance, 
researchers collaborate with translators 
(who are not part of the scientiﬁ  c 
investigation) in order to convey the 
content of the consent forms and 
information sheets in communities 
with ancestral oral traditions. Having 
investigators ﬂ  uent in local languages 
serves as a safeguard to ensure accurate 
translation. Messages recorded on 
audio or video tapes and played during 
the consent process have also been 
useful. As a longer-term intervention, 
researchers can work with linguists 
in “word creation”. Word creation 
involves relating a concept like 
“gene” to attributes of heredity that 
are already understood in the local 
language. To increase understanding, 
complementary creative approaches—
such as the use of drawings showing the 
scale of how much blood is being taken 
from a child’s body—may need to be 
employed. Comprehension assessment 
of consent should be used to both 
validate and reﬁ  ne these methods.
What is the purpose of research?
The consent form and information 
sheet, or their oral equivalents, will 
include an accessible and easily 
understandable explanation of the 
purpose of the research, for example:
Malaria is caused by a germ that is 
passed from one person to the other by 
the bite of a mosquito that carries the 
malaria germ. It can be particularly severe 
in children and may cause death. We do 
not know why some children become 
severely ill with malaria or why some of 
those children die from malaria. We think 
that some children are born with a better 
ability to resist malaria than others because 
of their genetic makeup (the way they are 
because of ancestry). To understand this 
problem, we need to study children who 
come to the hospital with severe malaria 
and compare them to children who have 
less severe malaria, to other children who 
are feeling well, and in some cases, to their 
healthy relatives.
What does participation involve?
The consent form and oral explanation 
will provide a clear and accessible 
description of what involvement in 
the research will mean, for example: 
What are the duration, procedures, and 
risks of the study? Will participation 
involve the taking of blood samples? 
Will it require home visits or visits to 
the clinic? Will participants be required 
to answer questions about their child’s 
health, or that of their relatives? How 
will complications that arise during 
research be handled? The distinction 
between research being conducted and 
treatment given should be made as clear 
as possible and the section should afﬁ  rm 
that treatment is not contingent upon 
participation in the research project.
When a child is admitted to hospital, 
it is usually necessary to take a blood 
sample for testing to ascertain the best 
treatment. This blood sample is not for 
research purposes but to help in the 
care of your child. In addition, we are 
requesting from parents or guardians 
of all children admitted to the hospital 
permission to collect a small extra amount 
of blood for research purposes. (Explain 
here the amount involved for the child 
in question—which may depend on 
their size—e.g., if the quantity is 2 ml the 
explanation might be “this will be about 
half a teaspoon-full”.) This sample will be 
collected at the same time as the blood 
samples taken for normal investigations. 
This will not harm your child in any way. 
If you do not wish to provide this extra 
blood sample, there are no negative 
consequences. Your child will receive the 
best possible treatment either way. 
Box 1. Elements of an Informed Consent Form Addressing 
Disclosure and Comprehension of Information
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Explaining the purpose and value of 
the research. Researchers must aim to 
develop, possibly using the techniques 
described above, a clear, concise, and 
simple way to explain why a study is 
being performed and how it may add 
to what is already known. Making 
clear in what way participation has 
the potential to contribute to a public 
good—e.g., the knowledge required 
to advance development of treatments 
for disease—is important not just to 
help explain the purpose of research 
but also to assist comprehension of 
why participation may be worthwhile. 
Community-based genetic studies may 
learn from vaccine trials: for instance, 
in safety trials of a malaria vaccine in 
Mali, researchers worked with a group 
of adults who subsequently volunteered 
for a genetic study after the study’s 
aims were discussed with community 
representatives and broadcast on 
local radio stations. In this case, the 
consent process started during the 
screening period and continued 
throughout the study with the purpose 
of delivering information to local 
administrative, health, and traditional 
authorities. After every procedure with 
volunteers, details on study conduct 
were explained and questions were 
answered. The most senior staff from 
the research group visited the study 
site and spoke with volunteers on a 
regular basis. At the end of the trial, an 
assembly—consisting of all volunteers 
and the full research staff—was held to 
receive feedback from volunteers on 
how the study was conducted.
In addition, an ofﬁ  cial ceremony 
was organized to present preliminary 
results (using non-technical language 
and clear visual aids) and to publicly 
acknowledge the participation of 
volunteers as contributors to the on-
going development of a malaria vaccine. 
It was conducted by the head of the 
administrative authority in the district, 
and was attended by international 
co-investigators, regional and district 
health authorities, traditional 
authorities, and all volunteers. It was 
found that public recognition and the 
feeling of real partnership contributed 
to the volunteers’ engagement with 
the study and comprehension of its 
purposes [14].
2.Voluntariness
In addition to being adequately 
understood and informed, consent 
must be voluntary—that is, free 
from coercion [8]. This means that 
participants must not come under 
undue pressure to participate while 
being informed about the potential 
value of the research.
Voluntariness and the relationship 
between research and clinical practice. 
Consent may be coerced in a number 
of ways. In resource-poor settings, 
for example, the provision of health 
care in research projects may act as 
an inducement. If participation in 
research is the only way for participants 
to gain access to clinical care, or 
if participants do not adequately 
understand the difference between 
research and clinical practice, this may 
mean that the decision to participate 
is not voluntary [18]. This can be 
compounded in genetic association 
studies of infectious diseases by the fact 
that blood for DNA samples is often 
collected during the acute clinical 
episode, making it almost impossible 
to clearly separate research from 
treatment.
Nevertheless, while complete 
separation of clinical practice from 
research may be difﬁ  cult to achieve 
in such settings, it is vital that 
researchers and those involved in 
community engagement activities 
take all steps they can to minimize 
inducement effects [19]. This includes 
making it clear (through repetition 
and comprehension assessment) 
to potential subjects that health-
care provision is not contingent on 
participation and ensuring that a 
similar level of health care is available 
to non-participating patients. 
Coercion could also occur as a result 
of traditional respect for health 
professionals, leading participants 
to feel that it would be impolite or 
that they are not “allowed” to refuse 
participation. It will be important to 
bear this possibility in mind in the 
development of consent processes.
3. Competence 
For consent to be valid it must also be 
competently given. Where research is to 
be carried out with young children, 
very elderly people, people with mental 
health problems, or people with 
potentially impaired decision-making 
ability for other reasons (such as 
distress, inﬂ  uence of medication, or ill-
health), researchers must take special 
precautions to ensure participants’ 
competence [20].
In cases of research on severe illness, 
the role of researchers and practicing 
clinicians may become blurred during 
consent processes. Dividing the consent 
process into two stages could help 
ensure that a vulnerable patient’s 
competence is not compromised by 
their illness or by distress. Clinicians 
might obtain consent for taking blood 
when a patient comes in for treatment 
during an acute clinical episode, but 
wait until a later stage, when the patient 
was not under immediate stress, to 
seek permission to use the blood in 
research. In remote settings, however, 
follow-up consent can be difﬁ  cult to 
achieve as it may prove difﬁ  cult to re-
contact patients once they have left the 
hospital setting.
Another issue is obtaining consent 
from older children and determining 
the age at which it is appropriate for a 
child to veto a parent’s consent. Rather 
than specifying an age threshold, 
it may be more appropriate for the 
investigator (with review from a local 
ethics board and following community 
consultation) to assess on a case-by-
case basis the child’s maturity and 
understanding.
4. Consent for the Future Use 
of Genetic Information
Another issue arising in relation to 
consent is the legitimacy of “broad” 
Box 2. Elements of an Informed 
Consent Form Addressing 
Voluntariness
How can the participant withdraw 
from research?
It will be made clear that the 
participant has the right to withdraw 
from research at any time and that this 
will have no negative consequences, 
particularly for treatment. This section 
will include an explanation of how to 
withdraw and, if applicable, a description 
of the provisions for withdrawal from 
future research.
Taking part in this study is entirely 
voluntary. You can withdraw your child 
from the study at any time. Not taking part 
in the study will not affect current or future 
medical care for your child in any way. If 
you decide to withdraw from the study 
later, please inform any member of staff or 
make an appointment with the principal 
investigator of the study. 
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consent. Is it acceptable to ask 
research participants to consent to 
the long-term storage of their genetic 
information for use in future, as 
yet undetermined, research? Such 
consent might be thought to be neither 
voluntary nor informed. However, it 
may be possible to impose limitations 
to “broad” consent [21]. For example, 
the scope of possible research could be 
narrowed to a speciﬁ  c disease, even if 
the exact nature of all possible future 
experiments was not clear at that stage. 
This could be complemented by an 
ongoing opt-out process such that 
participants can withdraw from any 
study at any future point in time, which 
would require appropriate processes 
for withdrawal to be developed 
beforehand.
Even with the “disease-speciﬁ  c” 
constraint, however, it still could be 
difﬁ  cult to communicate the nature of 
future, often highly technical research 
projects to participants, particularly in a 
developing-country context. In addition, 
even a disease-speciﬁ  c constraint 
might not be stringent enough to 
preclude the misuse of genetic data. 
For instance, genotyping haemoglobin 
allelic variants—something that could 
plausibly be done in a project related to 
malaria—can also reveal whether or not 
a child is biologically related to his or 
her parents.
There are other arguments against 
the disease-speciﬁ  c constraint. The 
potential importance of clinical 
and biological interactions between 
different diseases (e.g., interactions 
between nutrition, bacterial infection, 
and parasitic infection) presents a 
legitimate scientiﬁ  c rationale for 
expanding the range of use for stored 
samples beyond a single condition. 
Understanding general mechanisms of 
immune regulation (relevant both to 
bacterial and parasitic infections, for 
example) key to addressing malaria 
would be a case in point. Samples 
could also be useful for studying a vast 
number of other diseases, regardless of 
co-infection status.
Despite these problems, it is 
important to bear in mind the potential 
for previously collected genomic 
data to facilitate medical research in 
unforeseen ways. The potential value 
of such data is an important and highly 
signiﬁ  cant ethical consideration in its 
own right. The reuse of samples also 
allows researchers to collect fewer 
additional blood samples from very sick 
children. This would avoid the harms 
to participants inherent in collecting 
samples and the time and costs involved 
in organizing such collections. From an 
ethical standpoint, narrow approaches 
to consent have disadvantages as well as 
advantages.
The challenge is how to prevent 
or lessen the likelihood of the abuse 
of genetic data—say for paternity/
maternity testing or for research 
that could result in discrimination 
against an ethnic group—while still 
permitting scientists to engage in 
useful and ethical research. Alternative 
approaches to the disease-speciﬁ  c 
constraint on broad consent might be 
categorized as (1) institutional and (2) 
permissive.
Institutional approaches to broad 
consent could rely upon a well-
developed ethics infrastructure 
(including researchers’ ethics 
committees, local Institutional Review 
Boards, and funders’ oversight) to 
ensure that genetic data will only be 
used for projects that meet the criteria 
set out by these overlapping bodies. 
The International HapMap Project 
has adopted this approach [22]. If 
institutional capacity is not believed 
to be sufﬁ  cient in a particular locale, 
one might instead try to follow the 
permissive approach to consent, 
which describes all those things that a 
participant’s sample will not be used 
for, rather than restricting future use 
to research of a speciﬁ  c disease. From 
the perspective of protecting sample 
populations, there are advantages 
and disadvantages with each of 
these approaches. The nature of the 
research, characteristics of the sample 
What steps are being taken to ensure 
conﬁ  dentiality, security, and privacy?
The participant will be given an 
explanation of how their conﬁ  dentiality 
and privacy will be protected within the 
study and of what measures are being 
taken to ensure that data are secure. 
This will include particulars about who is 
granted access to personal information 
and will state that medical information 
collected will only be for the purposes of 
research.
Once we take a blood sample, we 
assign it a code number. By assigning your 
sample a number, we separate the name 
and any other personal information from 
the sample. Therefore, information about 
your child’s participation in this study 
will remain conﬁ  dential. In any reports, 
participants will be referred to by code 
number only. Participants’ names will 
not be used in any reports and will not 
be shared with anyone except the study 
investigators. All ﬁ  les with information 
that could identify you will be kept in a 
secure location, in case we need to talk to 
you in the future, and will not be released 
to anyone else.
What will happen to samples and 
records during and after research?
The form and oral explanation will 
include information about the time-
frame of research and whether genomic 
information that is being sampled will 
possibly be used for more than one 
study.  The extent of the participant’s 
consent will also be explained, e.g., 
whether consent is  limited to research 
on a speciﬁ  ed disease or at a single 
institution, or is permissive outside of 
speciﬁ  cally prohibited uses. If samples 
are to be stored after the end of the 
current study, precise information on 
how long and where samples will be 
retained must be included. Forms and 
explanations should separate the option 
of consenting to future research projects 
and consenting to the research project 
being conducted at that time.
We will test your child’s blood to see 
how it responds to malaria, and what 
your child inherited from his/her parents 
that may have affected his/her ability to 
respond to malaria. There are other tests 
to better understand malaria that we are 
not aware of now that we might wish to 
perform on your child’s samples. With your 
permission, the blood taken from your 
child’s arm will be kept and stored in our 
laboratory locally and in the laboratories 
of our partners abroad who are working 
with us on this research project. If you 
allow your child’s blood to be stored for 
research, any future projects using the 
blood sample would be approved by an 
ethics review board. However, you may 
choose not to have your child’s blood 
stored for future research and still be part 
of this study.
Box 3. Elements of an Informed Consent Form Addressing Future 
Use of Patient Information
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populations, and the likelihood 
that samples would be used for the 
beneﬁ  t of sample populations in the 
future should be used as criteria to 
determine which approach is settled 
upon. Identifying and addressing 
these considerations appropriately will 
require the development of innovative 
ways of involving local communities.
5. Community Dimensions 
of Consent
In our view, in many developing 
country settings, consent may be 
invalid if it does not have a familial or 
communal dimension. In all cases this 
will involve some level of community 
involvement and consultation in the 
research; in many cases, it will also 
require appropriate processes of 
community consent. However, tension 
may arise between individual and 
community consent; for example, 
if community elders decide that 
research should be participated in 
but individuals are unwilling, or if 
community leaders withhold consent 
but individuals want to participate. 
Community consent is no substitute for 
individual informed consent [4], but 
could be considered a precondition. 
For example, in the stepwise 
approach to consent utilized in malaria 
trials in Mali, community consent 
has been seen as the ﬁ  rst phase of 
a continuous process [14,23]. Even 
before seeking community consent, 
investigators should identify relevant 
ofﬁ  cial and unofﬁ  cial decision-
making structures that exist within 
communities. If such a multi-step 
approach is to work, each social unit 
consulted must have veto power; that is, 
only if all social units grant consent can 
it be considered valid.
The role of consent forms. While it 
is important to remember that valid 
consent cannot be attained solely with 
the completion of a consent form, 
such forms can play an important 
role. Among other things, a consent 
form can help to ensure that consent 
processes are comprehensive in 
information conveyed to a research 
participant. In large-scale genomic 
research, the consent form has an 
additional function: that of ensuring 
that key elements of the consent are 
standardized across research sites. 
It has been demonstrated in the 
United States that depending upon 
local institutional review to ensure 
uniformity of consent process in multi-
site research is problematic; such 
difﬁ  culties are likely to be much greater 
in very diverse and resource-poor 
settings [24]. It is important therefore 
that such collaborations themselves 
take on this responsibility. While a 
standardized consent form is not by 
itself sufﬁ  cient to ensure valid consent 
across research sites, it can contribute 
usefully to consistent practice.
The development of a consent 
form for use in a range of diverse 
sites needs to be ﬂ  exible enough to 
take into account local community 
and study-speciﬁ  c circumstances. The 
form will also need to address—in a 
relatively standard format—a number 
of key issues [25]. These have been 
broken out in Boxes 1–4 here and 
include: the purpose of the research, 
what participation involves, what will 
happen to samples and records during 
and after the research, what steps are 
being taken to ensure conﬁ  dentiality, 
security, and privacy, how participants 
can go about withdrawing from 
the research, and what beneﬁ  ts will 
accrue to researchers, individuals, and 
communities as a result of the project.
Conclusions
The tools of genomics have great 
potential for developing sustainable 
solutions to global health problems. 
As researchers cover new ground 
in understanding the fundamental 
molecular mechanisms of disease, we 
must make certain that sound ethical 
practices keep pace with scientiﬁ  c 
innovation. In this paper we have 
explored practical ethical issues arising 
in relation to the achievement of 
valid, community-informed consent 
in genomic epidemiological research. 
The achievement of valid consent 
for such research takes on particular 
importance in developing countries, 
both from the perspective of protecting 
individuals and building trust between 
communities and research groups. 
While funders, research institutions, 
and international policy makers have 
an important role in achieving valid 
consent, we have approached the issue 
from the perspective of scientists in the 
ﬁ  eld, for it is scientists who ultimately 
manage the interaction between 
laboratory and community.
Linking principles to practices at 
the ground level is the most powerful 
way to ensure that valid consent is 
indeed realized. In this paper we have 
highlighted a number of key areas 
of practice and policy relating to the 
achievement and understanding of 
valid consent in genomic epidemiology 
in developing countries. In turn, these 
have suggested a number of areas of 
practice in which embedded ethico-
social research would be of great value. 
These include: research into models 
of community consent and education 
for genomic epidemiology; the 
development of models for embedded 
empirical research on obtaining valid 
consent; research into the ethical and 
social factors important in building 
trust between communities and 
researchers; and research into the use 
of broad consent and the secondary 
research use of data and archived 
samples.  
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the way in which the research is expected 
to contribute to public knowledge will 
be included, and, where relevant, a 
statement of whether the research results 
will be used commercially.
Although there are no direct beneﬁ  ts for 
participating in this study, the knowledge 
that will be gained will help us develop new 
ways to control malaria that may beneﬁ  t 
people living in areas where malaria is 
a serious problem. It is hoped that our 
research will help scientists develop new 
treatments for malaria, although this may 
not occur for many years. If this occurs, 
neither researchers nor participants such 
as you or your child are expected to receive 
any ﬁ  nancial beneﬁ  ts. 
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